Adherence to highly active antiretroviral therapy in HIV-infected inmates

Current HIV Research

Volumn 6, Issue 2, 2008, Pages 164-170

  Inés, Sandra M ^a   Moralejo, Leticia ^a   Marcos, Miguel ^a   Fuertes, Aurelio ^a   Luna, Guillermo ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Acquired immunodeficiency syndrome; Highly active antiretroviral therapy; Patient compliance; Prisons

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ACADEMIC ACHIEVEMENT; ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; MULTIVARIATE ANALYSIS; OCCUPATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRISON; PRISONER; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; SPAIN; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS LOAD; VIRUS TRANSMISSION; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; IMMUNOLOGY; MIDDLE AGED; QUESTIONNAIRE; STATISTICS; TREATMENT REFUSAL; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRISONS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SPAIN; TREATMENT OUTCOME; TREATMENT REFUSAL; VIRAL LOAD;

EID: 41249092964     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783885047     Document Type: Review

References (27)

1. Pontali E. Antiretroviral treatment in correctional facilities. HIV Clin Trials 2005; 6: 25-37.
2. Soto Blanco JM, Perez IR, March JC. Adherence to antiretroviral therapy among HIV-infected prison inmates (Spain). Int J STD AIDS 2005; 16: 133-138.
3. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis 2002; 35: 305-312.
4. Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep 2005; 2: 165-170.
5. Griffin MM, Ryan JG, Briscoe VS, Shadle KM. Effects of incarceration on HIV-infected individuals. J Natl Med Assoc 1996; 88: 639-644.
6. Ford PM, Wobeser WL. Health care problems in prisons. CMAJ 2000; 162: 664-665.
7. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
8. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 2004; 38: 1754-1760.
9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
10. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 1099-1107.
11. Blanco JM, Perez IR, De Labry Lima AO, Recio JM, Lopez EG, Basanta JJ. Adherence to antiretroviral treatment in prisons. AIDS Res Hum Retroviruses 2005; 21: 683-688.
12. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28: 47-58.
13. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 341-348.
14. Wohl DA, Stephenson BL, Golin CE, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis 2003; 36: 1572-1576.
15. Moralejo L, Ines S, Marcos M, Fuertes A, Luna G. Factors influencing adherence to highly active antiretroviral therapy in Spain. Curr HIV Res 2006; 4: 221-227.
16. Gao X, Nau DP. Congruence of three self-report measures of medication adherence among HIV patients. Ann Pharmacother 2000; 34: 1117-1122.
17. Knobel H, Guelar A, Carmona A, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDs 2001; 15: 193-199.
18. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 261-268.
19. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16: 269-277.
20. Wagner GJ, Rabkin JG. Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care 2000; 12: 405-408.
21. Reynolds NR, Testa MA, Marc LG, et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav 2004; 8: 141-150.
22. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-449.
23. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretrovital therapy. J Acquir Immune Defic Syndr 2000; 25: 221-228.
24. Palepu A, Tyndall MW, Chan K, Wood E, Montanet JS, Hogg R.S. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther 2004; 9: 713-719.
25. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 2006; 42: 1619-1627.
26. White BL, Wohl DA, Hays RD, et al. A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy. AIDS Patient Care STDS 2006; 20: 408-417.
27. Rodrigo T, Cayla JA, Garcia de Olalla P, et al. Effectiveness of tuberculosis control programmes in prisons, Barcelona 1987-2000. Int J Tuberc Lung Dis 2002; 6: 1091-1097.